Palovarotene
 | |
| Systematic (IUPAC) name | |
|---|---|
|
4-[(E)-2-[5,5,8,8-tetramethyl-3-(1H-pyrazol-1-ylmethyl)-5,6,7,8-tetrahydronaphthalen-2-yl]ethenyl]benzoic acid | |
| Clinical data | |
| Legal status |
|
| Routes of administration | Oral |
| Identifiers | |
| ATC code | None |
| PubChem | CID 10295295 |
| ChemSpider | 8470763 |
| Chemical data | |
| Formula | C27H30N2O2 |
| Molar mass | 414.5393 g/mol |
| |
| |
Palovarotene (R-667, RO-3300074) is a highly selective retinoic acid receptor gamma (RAR-γ) agonist that is under investigation as a potential treatment for emphysema.[1] It is being developed by Roche. One such clinical trial found that palovarotene failed to produce any significant improvement in those with α1-antitrypsin deficiency-induced emphysema over a period of a year.[2]
References
- ↑ Hind, M; Stinchcombe, S (November 2009). "Palovarotene, a novel retinoic acid receptor gamma agonist for the treatment of emphysema". Current Opinion in Investigation Drugs 10 (11): 1243–1250. PMID 19876792.
- ↑ Stolk, J; Stockley, RA; Stoel, BC; Cooper, BG; Piitulainen, E; Seersholm, N; Chapman, KR; Burdon, JG; Decramer, M; Abboud, RT; Mannes, GP; Wouters, EF; Garrett, JE; Barros-Tizon, JC; Russi, EW; Lomas, DA; MacNee, WA; Rames, A (August 2012). "Randomised controlled trial for emphysema with a selective agonist of the c-type retinoic acid receptor". European Respiratory Journal 40 (2): 306–312. doi:10.1183/09031936.00161911. PMID 22282548.
This article is issued from Wikipedia - version of the Saturday, August 22, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.